FORTRESS BIOTECH INC (FBIO)
US34960Q3074 - Common Stock
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023
FBIO stock results show that Fortress Biotech beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fortress Biotech (NASDAQ:FBIO) just reported results for the fourth quarter of ...
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18...
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 ...
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024...
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET...
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical...
Fortress Biotech's Series A Preferred Stock Shares Cross 14.5% Yield Mark
Fortress Biotech to Participate in 36th Annual ROTH Conference
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for...
Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
New York, Feb 2, 2024 - (Plato Data via 500NewsWire) -- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang.
Journey Medical submits NDA for DFD-29 for rosacea (NASDAQ:DERM)
Journey Medical (FBIO) said it has submitted a New Drug Application for its rosacea treatment DFD-29. The product is being developed with Dr. Reddy's (RDY). Read more here.
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea...
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused...
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29...
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused...
Fortress Biotech's Series A Preferred Stock Crosses Above 16% Yield Territory
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
/PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today...
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales...
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023...